Mucofalk is developed by Russian Academy of Medical Sciences.

What development phase is Mucofalk in?

Mucofalk is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Mucofalk

Russian Academy of Medical Sciences · FDA-approved active Small molecule Quality 0/100

Mucofalk, marketed by the Russian Academy of Medical Sciences, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Mucofalk
Also known as	Psyllium
Sponsor	Russian Academy of Medical Sciences
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mucofalk CI brief — competitive landscape report
Mucofalk updates RSS · CI watch RSS
Russian Academy of Medical Sciences portfolio CI